February 14, 2023, San Diego, California — Ryne Biotechnology, Inc. (Ryne Bio), a therapeutics company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological disorders, announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4 million Clinical Stage Research Program (CLIN1) grant. This funding will enable the company to advance its lead candidate RNDP-001, an iPSC-derived dopamine neuron progenitor for the treatment of both inherited and idiopathic forms of Parkinson’s disease, through submission of an Investigational New Drug (IND) application within the next 12 months. [Read more…]
Heartseed and Novo Nordisk Dose First Patient with HS-001, an iPSC-Derived Cell Therapy to Treat Heart Failure
HS-001 consists of clusters of purified heart muscle cells derived from induced pluripotent stem cells (iPSCs).
Clinical phase 1/2 study (LAPiS Study) will enroll 10 patients with advanced heart failure caused by ischaemic heart disease.
Tokyo, Japan and Bagsværd, Denmark, 10 February 2023 – Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient, who lives with advanced heart failure and has given approval for the study to continue. [Read more…]
Interview With Kaz Hirao, President & COO at Fujifilm Cellular Dynamics
Fujifilm Cellular Dynamics is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.
The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.
4 Major Areas of Commercialization for iPS Cells
Since the discovery of induced pluripotent stem cells in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the stem cell type. In addition to this important basic research, a great deal of applied (“translational”) results has been done with the cell type. Induced pluripotent stem cells (also called iPS cells or iPSCs) are revolutionizing regenerative medicine because they represent a potential route for producing patient-specific stem cells for research or clinical use.
In the future, iPS cells will facilitate progress in personalized medicine by allowing a patient to use his or her own cells. In addition, iPSCs also show great promise in other areas, such as phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs under development, in short, facilitating the study of a “disease in a dish.”
Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors
FUKUOKA, Japan, and BORDEAUX, France / February 15th, 2023 – GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 64
- Next Page »
